The Library
Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution
Tools
Tools
Tools
Kerr, D. J., Young, Annie M., Neoptolemos, J. P., Sherman, M., Van-Geene, P., Stanley, A., Ferry, D., Dobbie, J. W., Vincke, B., Gilbert, J., el Eini, D., Dombros, N. and Fountzilas, G. (1996) Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. British Journal of Cancer, 74 (12). pp. 2032-2035. doi:10.1038/bjc.1996.672 ISSN 0007-0920.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1038/bjc.1996.672
Abstract
A novel peritoneal carrier solution, Icodextrin 20 (7.5%), has allowed exploration of prolonged, intraperitoneal (i.p.) infusion of the cytotoxic drug 5-fluorouracil (5-FU). A phase I and pharmacokinetic study was performed to determine the toxicities and maximum tolerated dose of prolonged and continuous intraperitoneal 5-FU in patients with peritoneal carcinomatosis. Seventeen patients were entered into this study. Each patient had a Tenckhoff catheter placed into the peritoneal cavity under general anaesthetic. After initial flushing and gradual increase in exchange volumes with Icodextrin 20, 5-FU was administered daily from Monday to Friday, 50% as a bolus in the exchange bag and 50% in an elastomeric infusor device delivering continuous 5-FU to the peritoneal cavity at 2 ml h-1. Treatment was continued for 12 weeks or until intolerable toxicity developed. Abdominal pain and infective peritonitis proved to be the main dose-limiting toxicities. Initial problems with infective peritonitis were overcome by redesign of the delivery system, and it proved possible to deliver 300 mg m-2 5-FU daily (5 days per week) for 12 weeks. Pharmacokinetic studies showed i.p. steady-state 5-FU concentrations (mean 47,500 ng ml-1) that were > 1000-fold higher than systemic venous levels (mean 30 ng ml-1).
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) | ||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | British Journal of Cancer | ||||
| Publisher: | Nature Publishing Group | ||||
| ISSN: | 0007-0920 | ||||
| Official Date: | 1 December 1996 | ||||
| Dates: |
|
||||
| Volume: | 74 | ||||
| Number: | 12 | ||||
| Page Range: | pp. 2032-2035 | ||||
| DOI: | 10.1038/bjc.1996.672 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
